Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116293 · ClinicalTrials.gov registry record
Effect of Testosterone Treatment on Drug Metabolism and Transport
A clinical trial of Transgender Persons, sponsored by University of Washington.
- Active
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT05116293: Active study of Transgender Persons, sponsored by University of Washington.
NCT05116293 is a study of Transgender Persons that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 12 participants, below the 303-participant average among 3 other Transgender Persons trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05116293, a study of Transgender Persons, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will evaluate the effect of gender-affirming testosterone treatment on how other medications are processed by the body.
Primary Outcome
ratio of the area under of the plasma concentration time curve (AUC) of midazolam in the presence to absence of gender-affirming testosterone treatment.
Conditions Studied
Interventions
- DRUG Midazolam oral solution
- DRUG Digoxin Oral Tablet
- DRUG Acetaminophen Oral Tablet
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT05116293 still lists
NCT05116293 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 303-participant average among 3 other Transgender Persons trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Transgender Persons appearing as the primary indexed condition, and to 3 interventions - of which Midazolam oral solution is the first listed.
NCT05116293 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05116293 about?
NCT05116293 is a clinical study titled "Effect of Testosterone Treatment on Drug Metabolism and Transport". This project will evaluate the effect of gender-affirming testosterone treatment on how other medications are processed by the body.
What is the current status of trial NCT05116293?
This trial is currently active not recruiting. The enrollment target is 12 participants. The study started on 2021-05-01. Estimated completion is 2025-12-31.
What conditions does trial NCT05116293 study?
This clinical trial studies the following conditions: Transgender Persons.
What interventions are being tested in trial NCT05116293?
The interventions under investigation include: Midazolam oral solution (DRUG), Digoxin Oral Tablet (DRUG), Acetaminophen Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT05116293?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05116293 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transgender Persons
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI